

MYELOPROLIFERATIVE NEOPLASMS AND PREGNANCY. EXPERIENCE OF FUNDENI MARROW TRANSPLANTATION CENTER.

Emilia Niculescu-Mizil, Iulia Ursuleac

Center of Haematology and Bone Marrow Transplantation Fundeni Clinical Institute

Chronic myeloproliferative neoplasms (MPN) have an increasing incidence and the age of diagnosed is becoming younger. Therefore, the pregnancy is a challenge for both haematologist, as well as obstetrician. It requires an appropriate therapeutic strategy that should be considered before pregnancy risk factors of patients (including thrombophilic status), history of pregnancies complications attributable to MPN, JAK2V617F mutation, increased risk of thrombosis associated with pregnancy (calculated to be 6 times higher), especially in the postpartum period. Treatment options include surveillance without treatment, phlebotomies, aspirin, low molecular weight heparin and therapy with interferon- α . In this paper we present experience of Fundeni Bone Marrow Transplantation Center about the management of pregnancy in MPN.